Napa Research LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$135,777	14
2023	Research	$482,830	59
2022	Research	$86,324	18
2021	Research	$10,673	6

Breakdown

Who paid Research payments · program years 2021–2024

Pfizer Inc. $474,803 61 payments
Chiesi USA, Inc. $101,778 24 payments
Amgen Inc. $77,867 4 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $44,669 3 payments
Avanir Pharmaceuticals, Inc. $15,188 4 payments
Swedish Orphan Biovitrum AB $1,300 1 payment

Studies the money was for Research payments · program years 2021–2024

An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $407,934 41 payments
An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 3Arm Study to Investigate Nirmatrelvirritonavir in Nonhospitalized Participants at Least 12 Years of Age With Symptomatic Covid19 Who Are Immunocompromised $51,438 10 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $47,254 9 payments
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $42,431 10 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $35,433 2 payments
P4 Uncontrolled Gout FORWARD $31,750 1 payment
P4 Uncontrolled Gout AGILE $22,450 1 payment
Ph2 RCT of Methotrexate to Increase Response in Patients with Uncontrolled Gout Receiving KRYSTEXXA $18,667 1 payment
20-Avp-786-306 $15,188 4 payments
A Phase 1 Openlabel Dose Escalation and Expansion Study of Pf07265028 As A Single Agent and in Combination With Sasanlimab Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Antitumor Activity of Pf07265028 in Participants With Advanced Or Metastatic Solid Tumors $12,600 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.